149 related articles for article (PubMed ID: 27062507)
1. Periodontal health in breast cancer patients on aromatase inhibitors versus postmenopausal controls: a longitudinal analysis.
Eagle I; Benavides E; Eber R; Kolenic G; Jung Y; Van Poznak C; Taichman LS
J Clin Periodontol; 2016 Aug; 43(8):659-67. PubMed ID: 27062507
[TBL] [Abstract][Full Text] [Related]
2. Periodontal Health in Women With Early-Stage Postmenopausal Breast Cancer Newly on Aromatase Inhibitors: A Pilot Study.
Taichman LS; Inglehart MR; Giannobile WV; Braun T; Kolenic G; Van Poznak C
J Periodontol; 2015 Jul; 86(7):906-16. PubMed ID: 25672657
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
Nogues X; Servitja S; Peña MJ; Prieto-Alhambra D; Nadal R; Mellibovsky L; Albanell J; Diez-Perez A; Tusquets I
Maturitas; 2010 Jul; 66(3):291-7. PubMed ID: 20399042
[TBL] [Abstract][Full Text] [Related]
4. Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors.
Cepa M; Vaz C
Acta Reumatol Port; 2015; 40(4):323-30. PubMed ID: 26922195
[TBL] [Abstract][Full Text] [Related]
5. Self-reported oral health and quality of life of postmenopausal breast cancer survivors on aromatase inhibitors and women without cancer diagnoses: a longitudinal analysis.
Taichman LS; Van Poznak CH; Inglehart MR
Support Care Cancer; 2016 Nov; 24(11):4815-24. PubMed ID: 27455851
[TBL] [Abstract][Full Text] [Related]
6. Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
Yonehara Y; Iwamoto I; Kosha S; Rai Y; Sagara Y; Douchi T
J Obstet Gynaecol Res; 2007 Oct; 33(5):696-9. PubMed ID: 17845332
[TBL] [Abstract][Full Text] [Related]
7. Prevention of osteoporosis as a consequence of aromatase inhibitor therapy in postmenopausal women with early breast cancer: rationale and design of a randomized controlled trial.
Kilbreath S; Refshauge KM; Beith J; Ward L; Sawkins K; Paterson R; Clifton-Bligh P; Sambrook PN; Simpson JM; Nery L
Contemp Clin Trials; 2011 Sep; 32(5):704-9. PubMed ID: 21570487
[TBL] [Abstract][Full Text] [Related]
8. Impact of chemotherapy followed by aromatase inhibitors on bone health of women with ER-positive early breast cancer in real world clinical settings in Greece: Results of the POCHARBI trial conducted by the Hellenic Society of Breast Surgeons.
Markopoulos C; Koukouras D; Venizelos V; Karyda I; Xepapadakis G; Misitzis J; Kalogerakos K; Poulakaki F; Natsiopoulos J; Zobolas V; Savidou C; Antonopoulou Z; Tzoracoleftherakis E
Breast; 2016 Jun; 27():27-34. PubMed ID: 27212697
[TBL] [Abstract][Full Text] [Related]
9. Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial.
Greenspan SL; Vujevich KT; Brufsky A; Lembersky BC; van Londen GJ; Jankowitz RC; Puhalla SL; Rastogi P; Perera S
Osteoporos Int; 2015 Jun; 26(6):1857-64. PubMed ID: 25792492
[TBL] [Abstract][Full Text] [Related]
10. Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.
Lee SA; Hwang SH; Ahn SG; Lee HM; Jeong J; Lee HD
Breast Cancer Res Treat; 2011 Dec; 130(3):863-70. PubMed ID: 21861101
[TBL] [Abstract][Full Text] [Related]
11. Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer.
Servitja S; Nogués X; Prieto-Alhambra D; Martínez-García M; Garrigós L; Peña MJ; de Ramon M; Díez-Pérez A; Albanell J; Tusquets I
Breast; 2012 Feb; 21(1):95-101. PubMed ID: 21924904
[TBL] [Abstract][Full Text] [Related]
12. Negative Impact of Aromatase Inhibitors on Proximal Femoral Bone Mass and Geometry in Postmenopausal Women with Breast Cancer.
Lee SJ; Kim KM; Brown JK; Brett A; Roh YH; Kang DR; Park BW; Rhee Y
Calcif Tissue Int; 2015 Dec; 97(6):551-9. PubMed ID: 26232103
[TBL] [Abstract][Full Text] [Related]
13. Aromatase inhibitors and mammographic breast density in postmenopausal women receiving hormone therapy.
Mousa NA; Crystal P; Wolfman WL; Bedaiwy MA; Casper RF
Menopause; 2008; 15(5):875-84. PubMed ID: 18480735
[TBL] [Abstract][Full Text] [Related]
14. Impact of aromatase inhibitors on bone health in breast cancer patients.
Geisler J; Lønning PE
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):294-9. PubMed ID: 19833206
[TBL] [Abstract][Full Text] [Related]
15. Higher than expected estradiol levels in aromatase inhibitor-treated, postmenopausal breast cancer patients.
Kunovac Kallak T; Baumgart J; Stavreus Evers A; Sundström Poromaa I; Moby L; Kask K; Norjavaara E; Kushnir MM; Bergquist J; Nilsson K
Climacteric; 2012 Oct; 15(5):473-80. PubMed ID: 22324859
[TBL] [Abstract][Full Text] [Related]
16. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
Cheung AM; Tile L; Cardew S; Pruthi S; Robbins J; Tomlinson G; Kapral MK; Khosla S; Majumdar S; Erlandson M; Scher J; Hu H; Demaras A; Lickley L; Bordeleau L; Elser C; Ingle J; Richardson H; Goss PE
Lancet Oncol; 2012 Mar; 13(3):275-84. PubMed ID: 22318095
[TBL] [Abstract][Full Text] [Related]
17. TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort.
María RS; Marta PM; Sonia S; Natalia GG; Tamara M; Ignasi T; Maria MG; Jaime RM; Adolfo DP; Joan A; Xavier N
Bone; 2016 Nov; 92():1-8. PubMed ID: 27519968
[TBL] [Abstract][Full Text] [Related]
18. Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial.
Prasad C; Greenspan SL; Vujevich KT; Brufsky A; Lembersky BC; van Londen GJ; Jankowitz RC; Puhalla SL; Rastogi P; Perera S
Bone; 2016 Sep; 90():123-6. PubMed ID: 27018037
[TBL] [Abstract][Full Text] [Related]
19. Potential role of bone-directed therapy on the superiority of aromatase inhibitors over tamoxifen.
Oyan B
Med Hypotheses; 2011 Dec; 77(6):1028-30. PubMed ID: 21930348
[TBL] [Abstract][Full Text] [Related]
20. Effects of aromatase inhibitor therapy on visceral adipose tissue area and cardiometabolic health in postmenopausal women with early and locally advanced breast cancer.
Cheung YM; Hoermann R; Van K; Wu D; Healy J; Chao M; White S; Yeo B; Zajac J; Grossmann M
Clin Endocrinol (Oxf); 2023 Feb; 98(2):190-201. PubMed ID: 36271726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]